8-K: Covista Unveils Growth Strategy, Strong Financial Targets

Covista Inc. announced its new 'Purpose at Scale' growth strategy and robust long-term financial targets through fiscal year 2029, while reaffirming strong fiscal year 2026 guidance.

Summary

• Covista introduced 'Purpose at Scale,' its new three-year growth strategy starting in FY27, focused on operational excellence, platform extension, employer integration, and technology.
• The company announced long-term financial targets for FY27-FY29, including revenue growth of 6-8% (FY27), 7-10% (FY28), and 8-11% (FY29), and adjusted EPS growth of 9-13% (FY27), 10-14% (FY28), and 12-16% (FY29).
• Covista reaffirmed its fiscal year 2026 guidance, projecting revenue between $1,900 million and $1,940 million (6% to 8.5% growth year-over-year) and adjusted earnings per share between $7.80 and $8.00 (17% to 20% growth year-over-year).
• The company has exceeded financial targets set three years ago, with FY26 guidance midpoint showing over $495 million incremental revenue and $7.90 adjusted EPS, compared to 2023 targets of $5.16-$5.97 adjusted EPS.
• Covista plans to increase total enrolled students to over 120,000 by the end of FY29, up from 97,000 currently.
• New strategic partnerships include GE Healthcare's HelloAI for AI fluency and SAIC for the Alliance for Advancing Rural Healthcare.
• The company's stock began trading under the new ticker symbol CVSA on the NYSE effective February 24, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive announcement, reflecting strong past performance, clear strategic direction, and ambitious yet achievable future growth targets in a critical industry sector.

Positives

• Exceeded financial targets set three years ago, demonstrating strong execution and performance.
• Reaffirmed robust FY26 guidance with projected revenue growth of 6-8.5% and adjusted EPS growth of 17-20%.
• Introduced a clear, multi-year growth strategy ('Purpose at Scale') with specific financial targets for FY27-FY29, indicating sustained growth.
• Strong student enrollment growth, reaching 97,000 students, up from 76,000 in June 2023.
• Graduated 24,000 healthcare professionals in FY25, including 10% of America's nurses and twice as many MDs as any other U.S. institution.
• Strategic partnerships with GE Healthcare's HelloAI and SAIC's Alliance for Advancing Rural Healthcare enhance technology leadership and address critical workforce needs.
• Maintained a strong balance sheet with $1.1 billion debt reduction since Q1 FY22 and a net leverage ratio of 0.9x in Q2 FY26.
• Returned $936 million to shareholders through share repurchases since Q3 FY22 at an average price of $54.
• Chamberlain University plans to open 10-15 new asset-light campuses by FY29, which are expected to be EBITDA positive within 24 months and accretive to margins.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those described.
• Important factors that could cause actual results to differ materially are disclosed in Item 1A. Risk Factors of the company's Annual Report on Form 10-K.
• Reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, which could be material to results in accordance with GAAP.

Future Outlook

Covista projects sustained profitable growth and long-term shareholder value through its 'Purpose at Scale' strategy, which aims to expand capacity, elevate student outcomes, and graduate practice-ready clinicians. The company anticipates continued revenue and adjusted EPS growth through FY29, driven by campus investments, scaling employer partnerships, and an improving program mix, while maintaining a disciplined capital allocation philosophy.

Management Comments

• "Over the past three years, we delivered what we promised: record enrollment, margin expansion and consistent execution. These results stand as a testament to our fundamental transformation from a diversified education company into essential infrastructure for America's healthcare workforce pipeline." Steve Beard, Chairman and CEO.
• "Tackling the healthcare workforce crisis requires infrastructure that operates at a scale traditional academic institutions cannot match." Steve Beard, Chairman and CEO.
• "The operational excellence we built during Growth with Purpose becomes the foundation for our next chapter, Purpose at Scale. Our distinct platform gives us the strategic flexibility to pursue capacity expansion, employer partnerships, AI-enabled curriculum transformation and new program development—all in parallel. That's a capability set no one else in our sector can match." Steve Beard, Chairman and CEO.
• "We are on track to exceed the financial targets we set three years ago. Guided by Purpose at Scale, we expect campus investments, scaling employer partnerships and improving program mix to drive our financial performance." Bob Phelan, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Covista's strategic pivot to focus entirely on healthcare workforce development positions it directly within a high-demand, structurally undersupplied market. The emphasis on AI-enabled education and employer integration aligns with broader industry trends seeking efficient, technology-driven solutions to address critical labor shortages in healthcare. Competitors in the traditional higher education sector often struggle to match Covista's scale and specialized focus, particularly in areas like nursing, medical, and veterinary education, where capacity constraints are significant.

Comparison to Industry Standards

• Covista graduated 24,000 healthcare professionals in FY25, more than any other U.S. institution.
• The company educates 10% of America's nurses, a significant share compared to the fragmented nursing education landscape.
• Covista educates twice as many MDs as any MD-granting school in the U.S., highlighting its unique scale in medical education.
• Ross University School of Veterinary Medicine (RUSVM) is the number one provider of Doctors of Veterinary Medicine to the U.S., demonstrating market leadership.
• Ross University School of Medicine (RUSM) boasts a 96% first-time residency attainment rate, which is competitive with or exceeds many U.S. medical schools, especially for students who may not gain admission to traditional U.S. MD programs.
• Walden University is ranked #1 for Masters of Social Work and #2 for Masters in Nursing, indicating strong program outcomes and market recognition.
• Chamberlain University is the largest nursing school in the U.S. and holds the #1 position in both Pre-Licensure and Post-Licensure Nursing, showcasing unparalleled scale and market dominance.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through sustained profitable growth, disciplined capital allocation, and share repurchases.
• Students: Expanded access to healthcare careers, enhanced learning experiences through AI and technology, and improved career outcomes through employer integration.
• Healthcare Systems/Employers: Strengthened workforce pipelines, access to practice-ready clinicians, and partnerships to address critical staffing shortages.
• Employees/Faculty: Focus on operational excellence and technology integration may lead to new skill development opportunities and potentially increased efficiency.

Next Steps

• Execute the 'Purpose at Scale' three-year growth strategy starting in FY27.
• Continue disciplined capital allocation, including M&A, partnerships, and share repurchases.
• Expand Chamberlain University's physical presence with 10-15 new campuses by FY29.
• Innovate the student experience with AI and technology, including an AI Powered Digital Classroom, an End-to-end Student Companion, and AI Powered Workforce and Operations.
• Accelerate new program development and expand undergraduate share at Walden University.
• Win share of clearly defined core customers and expand access via innovative pathways and partnerships in the Medical & Veterinary segment.

Key Dates

Recommendation

The filing presents a compelling case for a 'strong buy' recommendation. Covista has demonstrated a consistent track record of exceeding financial targets and executing its strategic vision. The new 'Purpose at Scale' strategy, coupled with robust long-term financial guidance for revenue and adjusted EPS growth through FY29, signals strong future performance in a high-demand sector. The company's dominant market position in healthcare education, strategic partnerships, disciplined capital allocation, and plans for capacity expansion (e.g., new Chamberlain campuses) further solidify its growth trajectory and ability to generate significant shareholder value. The focus on addressing critical healthcare workforce shortages at scale positions Covista as an indispensable asset in the U.S. healthcare infrastructure.

Keywords

healthcare education, workforce development, nursing education, medical education, veterinary medicine, AI in education, strategic plan, financial targets, enrollment growth, corporate governance, NYSE, CVSA